CrossMark

Meta-analysis using individual participant data from randomised trials: opportunities and limitations created by access to raw data

Ewelina Rogozińska,^{1,2} Nadine Marlin,³ Shakila Thangaratinam,^{1,2} Khalid S Khan,^{1,2} Javier Zamora^{1,4}

10.1136/ebmed-2017-110775

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ebmed-2017-110775>).

¹Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

²Department of Multidisciplinary Evidence Synthesis Hub (mEsh), Barts and the London School of Medicine, Queen Mary University of London, London, UK

³Pragmatic Clinical Trials Unit, Barts and the London School of Medicine, Queen Mary University of London, London, UK

⁴Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS) and CIBER Epidemiology and Public Health, Madrid, Spain

Correspondence to:

Ewelina Rogozińska, Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University London, London E1 2AB, UK; e.a.rogoszinska@qmul.ac.uk

Abstract

Meta-analysis based on individual participant data (IPD), often described as the 'gold standard' for effectiveness evidence synthesis, is increasingly being deployed despite being more resource intensive than collating study-level results. Its professed virtues include the ability to incorporate unreported data and to standardise variables and their definitions across trials. In reality, the unreported data, although present in shared datasets, might still not be usable in the analysis. The characteristics of trial participants and their outcomes may be too diversely captured for harmonisation and too time and resource consuming to standardise. Embarking on an IPD meta-analysis can lead to unanticipated challenges which ought to be handled with pragmatism. The aim of this article is to discuss the opportunities created by access to IPD and the practical limitations placed on such meta-analyses, using an international IPD meta-analysis of trials on the effect of lifestyle interventions in pregnancy as an example. Despite the increasing uptake of IPD meta-analysis, they encounter old problems shared by other research methods. When embarking on IPD meta-analysis, it is essential to evaluate the trade-offs between the ambitions, and what is achievable due to constraints imposed by the condition of collected IPD. Furthermore, incorporation of aggregate data from trials where IPD was not available should be a mandatory sensitivity analysis that makes the evidence synthesis up-to-date.

Introduction

Meta-analysis using individual participant data (IPD) is becoming increasingly popular, despite being a laborious and resource-intensive method of evidence synthesis compared with a standard review using study-level data.¹ It has the potential to overcome the limitations of meta-analyses based on published data through access to raw trial data,¹⁻⁴ such as standardisation of analysis methods and data across trials¹⁻⁵ (table 1). Access to IPD can facilitate integrity checks and intention to treat analysis by imputing for missing data. Collation of rarely reported variables for the key outcomes can result in greater precision of the intervention effect and address the problem of selective reporting.¹

Existing methodological literature focuses mainly on cost, team's expertise and management of the collaboration.³ Yet, not much is available on practical challenges associated with data harmonisation and their consequences for IPD meta-analyses. The aim of this article is to discuss some of the opportunities created by access

to IPD and the limitations of meta-analysis using IPD as indicated in table 1. We use the i-WIP IPD meta-analysis of 36 trials (12 526 participants from 16 countries; 50 investigators) on the effect of diet and physical activity-based interventions in pregnancy⁶ as an example (online supplementary appendix 1).

Standardisation of data across trials

Access to IPD should create a unique opportunity to unify all essential data. This is true assuming that collected data can be brought to the same format without losing their value. Routinely collected data such as age, weight or height tend to be captured as real values making them relatively easy to harmonise. Participant characteristics recorded in other formats or those less routinely collected can be much more challenging to standardise. One of the subgroups of interest in the project was maternal ethnic origin.⁷ The characteristic was available for 47% (17/36) trials of which one differentiated only between indigenous and non-indigenous women, four classified women only as Caucasian or non-Caucasian and eight declared to include only Caucasians or not recognise 'ethnicity' in their country. The characteristic was grouped into six categories (Caucasian, Asian, Afro-Caribbean, Central and South American, Middle Eastern and other and unknown) but due to a low proportion of women from groups other than Caucasian (>80% of included women) in the analysis of differential effects of intervention by ethnic origin, the characteristic was used in the binary format (Caucasian/non-Caucasian).⁶

Harmonisation of outcome definitions faced similar challenges. While some definitions are relatively easy to bring to a common format across the trials, for example, preterm birth, standardisation of others was simply not feasible. The task can be even more daunting when there is no consensus on classification methods, or the definitions changed over the years. Despite access to IPD, direct communication with the research teams and the idea endorsement by the members of the i-WIP collaborative group, standardisation of outcomes such as gestational diabetes (GDM) or caesarean section turned out to be unachievable within the study funding time. Diagnosis of GDM was based on a broad range of guidelines that followed algorithms that did not always overlap with each other. We have made an attempt to standardise the definitions of GDM and collected the blood test measurements used to diagnose the condition. However, the variability in glucose loads (50, 75 or 100 g) and tests' timing (fasting, 1 hour or 2 hours) leads us to abandon this task and acknowledge the variability in the outcome definition as a limitation. The variety of GDM definitions and the blood test measures, as well as

Table 1 Purported theoretical advantages of IPD meta-analysis of clinical trials and practical limitations in achieving them

Item	Practical challenges	Consequences
Standardisation of data across trials		
► Derive standard participant characteristics	► Diversity of characteristics and their coding ► Time and resources required to standardise them	► Loss of detail in characteristics through categorisation, for example, physical activity coded as any activity versus predominantly inactive ► Limits to clinical usefulness of analysis where covariates are coded in a crude way
► Analysis of subgroup effects and treatment–covariate interactions	► Poor recruitment of participants with a given characteristic in primary trials	► Unaddressed between-study heterogeneity ► Delay in the development of final dataset
► Derive standard outcome definitions	► Complexity or lack of consensus concerning outcome definition ► Time and resources required to standardise them	
Unreported outcomes		
► Incorporation of unreported outcomes	► Format of variables in shared datasets may prevent harmonisation	► For outcomes, data collected as mean change, lack of baseline and final values in dataset make them unusable in IPD meta-analysis
Role of IPD meta-analysis in dynamic research areas		
► Acquisition of IPD from all eligible trials	► Uncooperative trial investigators ► Lost or corrupted trial data ► Logistically unfeasible acquisition of IPD (trials identified late in the project life)	► Trials in the IPD meta-analysis might be substantially different in comparison with those for which IPD is not available ► The IPD meta-analysis does not reflect the totality of evidence on the subject and is at risk of being out-of-date
Other advantages listed in the literature*		
► Check the integrity of trial data	► Matching participants reported in trial publication and with those in shared datasets	► Delay in development of final dataset ► Dataset credibility
► Imputation of missing data	► Variation in reasons for data missingness across trials	► Effect sizes using imputed data may be harder to defend
► Incorporation of unpublished trials	► Data integrity could not be verified against peer-reviewed publication	► Potential undetectable data errors can have serious impact on the findings of the analysis and its reliability
► Analyse all important outcomes	► Lack of consensus among trialists and clinicians (core outcome set) means that important outcomes are not recorded in each study	► Evidence pooled for research-driven outcomes rather than for those critical and important to patient care

*As described in publications by Riley *et al*¹ and Tierney *et al*.⁵
IPD, individual participant data.

the coding of participants' ethnic origin in the trials with diet and/or physical activity in pregnancy, is presented in online supplementary appendix 2.

Unreported outcomes

Selective reporting of intervention effects depending on statistical significance is one of the most important sources of bias affecting clinical trials.^{8–11} Despite clear guidance on reporting of outcomes in the trial reports,¹² the problem persists, having a serious impact on the meta-analysis. In combination with variation in choice of trial outcomes,¹³ they are contributing to the serious waste of research efforts. More frequent reporting of statistically significant results can lead to a potential overestimation of underlying treatment effects in a meta-analysis when using data extracted from trial publications. IPD meta-analysis has the potential to address this problem through facilitating analysis of core outcome sets,¹⁴ if available in trial datasets but not reported in publications.

Access to individual records should increase the number of trials included in the analysis and enhance the quality of outcome data. However, the benefits may not always be substantial. In the i-WIP project, the number of trials with the outcomes of interest was higher through access to IPD in comparison with data extracted from publications (online supplementary appendix 3). In addition, use of the raw data to generate outcomes not considered in original trials (eg, use of gestational age at delivery to define the occurrence of prematurity) may lead to a substantial increase in the number of the trial that can be incorporated into the meta-analysis (table 2). Nevertheless, the presence of data in the dataset did not always allow to incorporate a given dataset in the statistical analysis. Too few events (eg, stillbirths) and lack of all measures (baseline and final for weight gain) prevented trial inclusion. Still, in the example, incorporation of trials with previously unavailable outcome data changed the value of the

effect estimate by more than 10% in three outcomes and its statistical significance in one (table 2).

The addition of unreported data may or may not lead to a change in funnel plot asymmetry. In the example, incorporation of unpublished outcomes in the meta-analysis for admission to neonatal intensive care unit has not revealed any potential bias. Similarly, for small for gestational age infant where outcome data were generated using raw data, if the outcome was not considered in original trials (table 2). For continuous outcomes (gestational weight gain in the example), the change in the plot asymmetry might also occur due to the standardisation of the analysis methods rather than incorporation of unreported data (figure 1).

Role of IPD meta-analysis in dynamic research areas

The authors of guidance on the appraisal of IPD meta-analyses of randomised trials advocate checking for the proportion of trials from which IPD was obtained.⁵ A recent study showed that only 25% of evaluated IPD meta-analyses obtained 100% of identified trial data.¹⁵ Acquisition of all eligible trials can be challenging for numerous reasons, with uncooperative trial investigators mentioned most commonly.⁵ IPD meta-analysis is a lengthy and resource-intensive process which can also decrease the chance of complying with the above-mentioned recommendation.

Since the publication of the systematic review that laid the grounds for the IPD meta-analysis we used as an example,¹⁶ there has been a significant increase in the number of trials evaluating the effects of diet and/or physical activity-based interventions in pregnancy. Between the end of data acquisition in June 2015 to February 2017, findings from additional 45 trials have been published (figure 2) making achieving the goal of being up-to-date and obtaining the majority of IPD virtually impossible.¹⁷ In combination with the trials for

Table 2 Meta-analysis of trials with diet and/or physical activity-based interventions in pregnancy with available IPD

Outcome	Meta-analysis	Trials (n)	Women (n)	Effect estimate*	95% CI	Test for funnel plot asymmetry†
Gestational weight gain	Published data	27	8697	−1.01	(−1.41 to 0.61)	0.14
	IPD	32	9320	−0.70	(−0.92 to 0.48)	0.04
Gestational diabetes	Published data	18	8898	0.86	(0.67 to 1.10)	0.04
	IPD	27	9427	0.89	(0.72 to 1.10)	0.03
Preterm delivery	Published data	17	9003	0.79	(0.63 to 0.99)	0.64
	IPD	32	11 676	0.94	(0.78 to 1.13)	0.32
Any caesarean section	Published data	23	9178	0.91	(0.83 to 1.00)	0.13
	IPD	32	11 410	0.91	(0.83 to 0.99)	0.88
Small-for-gestational age	Published data	5	2807	1.19	(0.92 to 1.54)	NA
	IPD	33	11 666	1.06	(0.94 to 1.20)	0.74
Large for gestational age	published data	10	5583	0.90	(0.70 to 1.14)	0.72
	IPD	34	12 047	0.90	(0.76 to 1.07)	0.86
Admission to NICU	Published data	5	5387	1.02	(0.89 to 1.18)	NA
	IPD	16	8140	1.01	(0.84 to 1.23)	0.44

*Mean difference for gestational weight gain and OR for binary outcomes.

†Egger's test for gestational weight gain and Peter's test for binary outcomes.

IPD, individual participant data; NA, not applicable due to number of observations; NICU, neonatal intensive care unit.

Figure 1 Comparison of funnel plots between meta-analyses using published and Individual Participant Data (IPD).

which IPD was sought but not obtained, the number of trials outside the IPD meta-analysis (non-IPD studies) constituted 65% of trials (67/103 trials) and 51% of women randomised to all eligible trials (12960/25486). The meta-analysis combining IPD with non-IPD studies showed a stronger overall effect of interventions in reduction of gestational weight gain and a significant reduction of odds for GDM than one using only IPD.¹⁷

Summary

Despite the advantages of meta-analysis using IPD, the method encounters problems faced by other research methods such as uncooperative investigators or incompleteness of records. The IPD meta-analysis is a resource-demanding approach to evidence synthesis

and requires a thorough evaluation of what is achievable. It might be that we will need to accept that some primary research is not usable for evidence synthesis. Mapping of definitions and additional data that could help to standardise the outcome across the trials may not tackle all the issues but will facilitate the smoother conduct of IPD meta-analyses. The efforts associated with obtaining IPD and its harmonisation need to be balanced by the potential gains achievable through a complex and profound statistical analysis. Prospectively designed IPD meta-analyses have the potential to overcome some of the challenges described in this article as they tend to collect data in a preagreed format.¹⁸ Promotion of consensus on the research standards with regard to outcome definitions, capturing of participants'

Figure 2 Number of randomised controlled trials with diet and/or physical activity-based interventions provided antenatally.

characteristics and effective ways of implementing them in the trials should help to reduce the potential research waste. Finally, putting the findings of IPD meta-analysis into a context of the totality of evidence is paramount for the validity of results.⁵ Currently, guidelines recommend adding non-IPD studies to IPD meta-analysis when a substantial proportion of trials IPD was not obtained at the beginning of the project. In addition, in some areas of medical research, the amount of evidence generated annually makes it difficult to stay up-to-date while conducting IPD meta-analysis. Therefore, adding newly published trials is as important as incorporating the not shared ones.

Twitter Follow Ewelina Rogozinska @EaRogozinska

Acknowledgements We would like to acknowledge all members of Collaborative Group who contributed their trial data to the i-WIP IPD meta-analysis funded by The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (No.12/01/50).

Contributors ER wrote the initial draft of the manuscript and all subsequent drafts after critical review by JZ, NM and KSK. ER is a guarantor for the manuscript.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

- Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;340:c221.
- Lambert PC, Sutton AJ, Abrams KR, *et al.* A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. *J Clin Epidemiol* 2002;55:86–94.
- Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. *Eval Health Prof* 2002;25:76–97.
- Tudur Smith C, Marucci M, Nolan SJ, *et al.* Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *Cochrane Database Syst Rev* 2016;9:MR000007.
- Tierney JF, Vale C, Riley R, *et al.* Individual Participant Data (IPD) meta-analyses of randomised controlled trials: guidance on their use. *PLoS Med* 2015;12:e1001855.
- Rogozinska E, Marlin N, Jackson L, *et al.* Effects of antenatal diet and physical activity on maternal and fetal outcomes: individual patient data meta-analysis and health economic evaluation. *Health Technol Assess* 2017;21:1–158.
- Ruifrok AE, Rogozinska E, van Poppel MN, *et al.* Study protocol: differential effects of diet and physical activity based interventions in pregnancy on maternal and fetal outcomes—individual patient data (IPD) meta-analysis and health economic evaluation. *Syst Rev* 2014;3:131.
- Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. *Stat Med* 2005;24:1547–61.
- Williamson PR, Gamble C, Altman DG, *et al.* Outcome selection bias in meta-analysis. *Stat Methods Med Res* 2005;14:515–24.
- Kirkham JJ, Dwan KM, Altman DG, *et al.* The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;340:c365.
- Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. *BMJ* 2005;330:753.
- Moher D, Hopewell S, Schulz KF, *et al.* CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.
- Clarke M. Standardising outcomes for clinical trials and systematic reviews. *Trials* 2007;8:39.
- Clarke M, Williamson PR. Core outcome sets and systematic reviews. *Syst Rev* 2016;5:11.

15. Nevitt SJ, Marson AG, Davie B, *et al.* Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review. *BMJ* 2017;357:j1390.
16. Thangaratinam S, Rogozinska E, Jolly K, *et al.* Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. *BMJ* 2012;344:e2088.
17. Rogozinska E, Marlin N, Betran AP, *et al.* Effect of diet and physical activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual participant data from randomised trials. *BMJ* 2017;358:j3119.
18. Ganzevoort W, Alfirevic Z, von Dadelszen P, *et al.* STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. *Syst Rev* 2014;3:23.